RxDoctor Payments Data

Michelle Black, APRN

Family · Bowling Green, KYNPI 1053411132

Payments from drug & device makers

$6,734in general payments, 2019–2025

Across 364 payments — averaging $18.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$854
  • Novartis$530
  • Pfizer$452
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$452
  • Amgen$270
  • Grifols USA, LLC$265
  • plus $4K from 49 others

What the payments were for

  • Food & beverage$6,64499%
  • Education$901%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,734 in reported general payments places this provider in the 95th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$3,062
Medicare patients
32
Services billed
54

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban442$373,563
XareltoRivaroxaban131$134,855
EntrestoSacubitril/Valsartan48$45,695
MultaqDronedarone Hcl28$40,832
BrilintaTicagrelor50$38,587
Dofetilide214$34,067
Repatha SureclickEvolocumab13$20,190
Ranolazine ErRanolazine169$14,688
Metoprolol Succinate772$8,137
Potassium Chloride289$7,177
Prasugrel Hcl69$6,512
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$4,277
Dabigatran EtexilateDabigatran Etexilate Mesylate14$3,053
Flecainide Acetate62$2,569
Losartan Potassium282$2,527

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$452$373,563442 claims
Johnson & JohnsonXarelto$854$134,855131 claims
NovartisEntresto$530$45,69548 claims
Sanofi-aventis U.S. LLCMultaq$247$40,83228 claims
AstraZenecaBrilinta$135$38,58750 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,374 family providers in Kentucky.

Other family in Bowling Green

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →